{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T17:02:10Z","timestamp":1770483730872,"version":"3.49.0"},"reference-count":94,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,7,18]],"date-time":"2013-07-18T00:00:00Z","timestamp":1374105600000},"content-version":"vor","delay-in-days":778,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1016\/j.rmed.2010.12.018","type":"journal-article","created":{"date-parts":[[2011,1,27]],"date-time":"2011-01-27T04:35:24Z","timestamp":1296102924000},"page":"818-827","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"title":["Treatment of pulmonary arterial hypertension: The role of prostacyclin and prostaglandin analogs"],"prefix":"10.1016","volume":"105","author":[{"given":"Zeenat","family":"Safdar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmed.2010.12.018_bib1","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1016\/j.jacc.2009.04.011","article-title":"Diagnosis and assessment of pulmonary arterial hypertension","volume":"54","author":"Badesch","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.rmed.2010.12.018_bib2","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.jacc.2009.01.004","volume":"53","author":"McLaughlin","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.rmed.2010.12.018_bib3","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1093\/eurheartj\/ehp297","volume":"30","author":"Galie","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.rmed.2010.12.018_bib4","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/01.hco.0000231410.07426.9b","article-title":"An evidence-based approach to the management of pulmonary arterial hypertension","volume":"21","author":"Archer","year":"2006","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.rmed.2010.12.018_bib5","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1016\/j.clinthera.2007.10.009","article-title":"Evidence-based pharmacologic management of pulmonary arterial hypertension","volume":"29","author":"Benedict","year":"2007","journal-title":"Clin Ther"},{"key":"10.1016\/j.rmed.2010.12.018_bib6","doi-asserted-by":"crossref","first-page":"343","DOI":"10.7326\/0003-4819-115-5-343","article-title":"Survival in patients with primary pulmonary hypertension. Results from a national prospective registry","volume":"115","author":"D\u2019Alonzo","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.rmed.2010.12.018_bib7","doi-asserted-by":"crossref","first-page":"205S","DOI":"10.1378\/chest.114.3_Supplement.205S","article-title":"Lipid mediator dysregulation in primary pulmonary hypertension","volume":"114","author":"Christman","year":"1998","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2010.12.018_bib8","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1164\/ajrccm.159.6.9804054","article-title":"Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension","volume":"159","author":"Tuder","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmed.2010.12.018_bib9","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/j.jacc.2009.04.012","article-title":"Updated clinical classification of pulmonary hypertension","volume":"54","author":"Simonneau","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.rmed.2010.12.018_bib10","unstructured":"Rich S. Executive Summary from the World Symposium on Primary Pulmonary Hypertension 1998. Evian, France, 6\u201310 September 1998; [cited 2009 October 23]; Available from, http:\/\/web.archive.org\/web\/20020214220427\/www.who.int\/ncd\/cvd\/pph.html."},{"key":"10.1016\/j.rmed.2010.12.018_bib11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.rmed.2009.07.015","article-title":"A review of prostaglandin analogs in the management of patients with pulmonary arterial hypertension","volume":"104","author":"Mubarak","year":"2010","journal-title":"Respir Med"},{"key":"10.1016\/j.rmed.2010.12.018_bib12","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1016\/j.jacc.2009.04.017","article-title":"Updated evidence-based treatment algorithm in pulmonary arterial hypertension","volume":"54","author":"Barst","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.rmed.2010.12.018_bib13","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1016\/j.jacc.2009.04.007","article-title":"End points and clinical trial design in pulmonary arterial hypertension","volume":"54","author":"McLaughlin","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.rmed.2010.12.018_bib14","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/S0140-6736(84)91452-1","article-title":"Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin)","volume":"1","author":"Higenbottam","year":"1984","journal-title":"Lancet"},{"key":"10.1016\/j.rmed.2010.12.018_bib15","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0090-6980(80)90030-1","article-title":"Effects of intravenous infusion of prostacyclin (PGI2) in man","volume":"19","author":"O\u2019Grady","year":"1980","journal-title":"Prostaglandins"},{"key":"10.1016\/j.rmed.2010.12.018_bib16","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1183\/09031936.00097107","article-title":"Prostacyclin therapies for the treatment of pulmonary arterial hypertension","volume":"31","author":"Gomberg-Maitland","year":"2008","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmed.2010.12.018_bib17","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/j.jacc.2008.01.024","article-title":"Pulmonary arterial hypertension","volume":"51","author":"Chin","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.rmed.2010.12.018_bib18","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/NAN.0b013e31818c09b1","article-title":"Advances in prostanoid infusion therapy for pulmonary arterial hypertension","volume":"31","author":"Doran","year":"2008","journal-title":"J Infusion Nurs"},{"key":"10.1016\/j.rmed.2010.12.018_bib19","author":"GlaxoSmithKline"},{"key":"10.1016\/j.rmed.2010.12.018_bib20","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1164\/ajrccm.164.2.2010150","article-title":"Prostacyclin receptor-dependent modulation of pulmonary vascular remodeling","volume":"164","author":"Hoshikawa","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmed.2010.12.018_bib21","author":"Teva Pharmaceuticals"},{"key":"10.1016\/j.rmed.2010.12.018_bib22","series-title":"Highlights of prescribing information, epoprostenol for injection, 1.5 mg\/vial","author":"Center for Drug Evaluation and Research","year":"2008"},{"key":"10.1016\/j.rmed.2010.12.018_bib23","author":"Actelion Pharmaceuticals US, Inc"},{"key":"10.1016\/j.rmed.2010.12.018_bib24","author":"GeneraMedix"},{"key":"10.1016\/j.rmed.2010.12.018_bib25","unstructured":"Center for Drug Evaluation and Research. Application number: 22\u2013260, Other Review(s). 2008."},{"key":"10.1016\/j.rmed.2010.12.018_bib26","unstructured":"Center for Drug Evaluation and Research. Application number: 22\u2013260, Medical Review(s). 2008."},{"key":"10.1016\/j.rmed.2010.12.018_bib27","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1164\/ajrccm.162.5.2004042","article-title":"Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension","volume":"162","author":"Aguilar","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmed.2010.12.018_bib28","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7326\/0003-4819-132-6-200003210-00002","article-title":"Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial","volume":"132","author":"Badesch","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.rmed.2010.12.018_bib29","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJM199602013340504","article-title":"A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group","volume":"334","author":"Barst","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmed.2010.12.018_bib30","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1002\/1529-0131(199912)42:12<2638::AID-ANR20>3.0.CO;2-X","article-title":"Systemic sclerosis-associated pulmonary hypertension: short- and long-term effects of epoprostenol (prostacyclin)","volume":"42","author":"Klings","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rmed.2010.12.018_bib31","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1161\/01.CIR.0000029100.82385.58","article-title":"Survival in primary pulmonary hypertension: the impact of epoprostenol therapy","volume":"106","author":"McLaughlin","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.rmed.2010.12.018_bib32","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0735-1097(97)00187-3","article-title":"Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion","volume":"30","author":"Shapiro","year":"1997","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.rmed.2010.12.018_bib33","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0735-1097(02)02012-0","article-title":"Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival","volume":"40","author":"Sitbon","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.rmed.2010.12.018_bib34","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1378\/chest.07-1992","article-title":"Transition from IV to subcutaneous prostacyclin: premature withdrawal?","volume":"132","author":"Shapiro","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2010.12.018_bib35","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.healun.2010.03.008","article-title":"Prostacyclin administration errors in pulmonary arterial hypertension patients admitted to hospitals in the United States: a national survey","volume":"29","author":"Kingman","year":"2010","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.rmed.2010.12.018_bib36","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1358\/dot.2004.40.3.820086","article-title":"Overview of treprostinil sodium for the treatment of pulmonary arterial hypertension","volume":"40","author":"Budev","year":"2004","journal-title":"Drugs Today"},{"key":"10.1016\/j.rmed.2010.12.018_bib37","author":"United Therapeutics"},{"key":"10.1016\/j.rmed.2010.12.018_bib38","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1517\/14656566.9.8.1415","article-title":"Treprostinil for the treatment of pulmonary hypertension","volume":"9","author":"Skoro-Sajer","year":"2008","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.rmed.2010.12.018_bib39","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1378\/chest.07-2111","article-title":"Treprostinil-based therapy in the treatment of moderate-to-severe pulmonary arterial hypertension: long-term efficacy and combination with bosentan","volume":"134","author":"Benza","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2010.12.018_bib40","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1378\/chest.129.6.1636","article-title":"Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension","volume":"129","author":"Lang","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2010.12.018_bib41","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/00005344-200302000-00019","article-title":"Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension","volume":"41","author":"McLaughlin","year":"2003","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.rmed.2010.12.018_bib42","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1378\/chest.126.2.420","article-title":"Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease","volume":"126","author":"Oudiz","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2010.12.018_bib43","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1164\/ajrccm.165.6.2106079","article-title":"Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial","volume":"165","author":"Simonneau","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmed.2010.12.018_bib44","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1378\/chest.129.3.683","article-title":"Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial","volume":"129","author":"Tapson","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2010.12.018_bib45","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/00005344-200408000-00010","article-title":"Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers","volume":"44","author":"Laliberte","year":"2004","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.rmed.2010.12.018_bib46","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.4049\/jimmunol.178.3.1628","article-title":"Synthetic prostacyclin analogs differentially regulate macrophage function via distinct analog-receptor binding specificities","volume":"178","author":"Aronoff","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.rmed.2010.12.018_bib47","doi-asserted-by":"crossref","first-page":"702","DOI":"10.4049\/jimmunol.178.2.702","article-title":"Prostaglandin I2 analogs inhibit proinflammatory cytokine production and T cell stimulatory function of dendritic cells","volume":"178","author":"Zhou","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.rmed.2010.12.018_bib48","author":"Rich"},{"key":"10.1016\/j.rmed.2010.12.018_bib49","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1183\/09031936.06.00044406","article-title":"Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil","volume":"28","author":"Barst","year":"2006","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmed.2010.12.018_bib50","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJM199605303342214","article-title":"Intravenous epoprostenol for primary pulmonary hypertension","volume":"334","author":"Schulze-Neick","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmed.2010.12.018_bib51","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1183\/09031936.00169608","article-title":"Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension","volume":"33","author":"Jing","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmed.2010.12.018_bib52","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2147\/VHRM.S3223","article-title":"Inhaled iloprost for the control of pulmonary hypertension","volume":"5","author":"Krug","year":"2009","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.rmed.2010.12.018_bib53","author":"Actelion Pharmaceuticals US, Inc"},{"key":"10.1016\/j.rmed.2010.12.018_bib54","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1183\/09031936.00068009","article-title":"Intravenous iloprost for pulmonary arterial hypertension: still waiting for evidence","volume":"34","author":"Provencher","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmed.2010.12.018_bib55","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1183\/09031936.03.00057703","article-title":"Inhaled iloprost is a potent acute pulmonary vasodilator in HIV-related severe pulmonary hypertension","volume":"23","author":"Ghofrani","year":"2004","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmed.2010.12.018_bib56","doi-asserted-by":"crossref","first-page":"435","DOI":"10.7326\/0003-4819-132-6-200003210-00003","article-title":"Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH Study Group","volume":"132","author":"Olschewski","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.rmed.2010.12.018_bib57","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1164\/ajrccm.160.2.9810008","article-title":"Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis","volume":"160","author":"Olschewski","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmed.2010.12.018_bib58","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa020204","article-title":"Inhaled iloprost for severe pulmonary hypertension","volume":"347","author":"Olschewski","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmed.2010.12.018_bib59","first-page":"760","article-title":"Sustained success of therapy with inhaled iloprost for severe pulmonary arterial hypertension associated with systemic sclerosis and pulmonary fibrosis","volume":"25","author":"Ahmadi-Simab","year":"2007","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.rmed.2010.12.018_bib60","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ijcard.2006.01.067","article-title":"Evaluation of pulmonary vascular response to inhaled iloprost in heart transplant candidates with pulmonary venous hypertension","volume":"115","author":"Braun","year":"2007","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.rmed.2010.12.018_bib61","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1056\/NEJM200006223422503","article-title":"Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue","volume":"342","author":"Hoeper","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmed.2010.12.018_bib62","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.rmed.2010.01.008","article-title":"Long-term therapy with inhaled iloprost in patients with pulmonary hypertension","volume":"104","author":"Olschewski","year":"2010","journal-title":"Respir Med"},{"key":"10.1016\/j.rmed.2010.12.018_bib63","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1164\/rccm.200603-358OC","article-title":"Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension","volume":"174","author":"McLaughlin","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmed.2010.12.018_bib64","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1378\/chest.124.4.1294","article-title":"Pharmacodynamics and pharmacokinetics of inhaled iloprost, aerosolized by three different devices, in severe pulmonary hypertension","volume":"124","author":"Olschewski","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2010.12.018_bib65","doi-asserted-by":"crossref","first-page":"820","DOI":"10.7326\/0003-4819-124-9-199605010-00006","article-title":"Aerosolized prostacyclin and iloprost in severe pulmonary hypertension","volume":"124","author":"Olschewski","year":"1996","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.rmed.2010.12.018_bib66","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1476-7120-5-41","article-title":"Acute hemodynamic effect of inhaled iloprost in pulmonary artery hypertension evaluated with echocardiography","volume":"5","author":"Loureiro","year":"2007","journal-title":"Cardiovasc Ultrasound"},{"key":"10.1016\/j.rmed.2010.12.018_bib67","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1159\/000101953","article-title":"Effect of inhaled iloprost during off-medication time in patients with pulmonary arterial hypertension","volume":"74","author":"Mereles","year":"2007","journal-title":"Respiration"},{"key":"10.1016\/j.rmed.2010.12.018_bib68","author":"United Therapeutics"},{"key":"10.1016\/j.rmed.2010.12.018_bib69","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/j.jacc.2006.05.070","article-title":"Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension","volume":"48","author":"Channick","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.rmed.2010.12.018_bib70","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/j.jacc.2006.06.062","article-title":"Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies","volume":"48","author":"Voswinckel","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.rmed.2010.12.018_bib71","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2147\/VHRM.S2477","article-title":"Treprostinil for pulmonary hypertension","volume":"4","author":"Skoro-Sajer","year":"2008","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.rmed.2010.12.018_bib72","author":"United Therapeutics"},{"key":"10.1016\/j.rmed.2010.12.018_bib73","author":"United Therapeutics"},{"key":"10.1016\/j.rmed.2010.12.018_bib74","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S0002-9149(96)90408-7","article-title":"Short-term hemodynamic effect of a new oral PGI2 analogue, beraprost, in primary and secondary pulmonary hypertension","volume":"78","author":"Saji","year":"1996","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.rmed.2010.12.018_bib75","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1177\/000331979804900210","article-title":"Beneficial hemodynamic effects of oral prostacyclin (PGI2) analogue, beraprost sodium, on a patient with primary pulmonary hypertension \u2013 a case report","volume":"49","author":"Hashida","year":"1998","journal-title":"Angiology"},{"key":"10.1016\/j.rmed.2010.12.018_bib76","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1136\/heart.86.6.661","article-title":"Long term treatment of pulmonary arterial hypertension with beraprost, an oral prostacyclin analogue","volume":"86","author":"Vizza","year":"2001","journal-title":"Heart"},{"key":"10.1016\/j.rmed.2010.12.018_bib77","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0735-1097(02)01786-2","article-title":"Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial","volume":"39","author":"Galie","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.rmed.2010.12.018_bib78","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2165\/00003495-200262010-00005","article-title":"Beraprost: a review of its pharmacology and therapeutic efficacy in the treatment of peripheral arterial disease and pulmonary arterial hypertension","volume":"62","author":"Melian","year":"2002","journal-title":"Drugs"},{"key":"10.1016\/j.rmed.2010.12.018_bib79","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1136\/heart.87.4.340","article-title":"Oral beraprost sodium improves exercise capacity and ventilatory efficiency in patients with primary or thromboembolic pulmonary hypertension","volume":"87","author":"Nagaya","year":"2002","journal-title":"Heart"},{"key":"10.1016\/j.rmed.2010.12.018_bib80","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1046\/j.1442-200X.2002.01597.x","article-title":"Beraprost sodium for pulmonary hypertension with congenital heart disease","volume":"44","author":"Suzuki","year":"2002","journal-title":"Pediatr Int"},{"key":"10.1016\/j.rmed.2010.12.018_bib81","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/S0735-1097(03)00463-7","article-title":"Beraprost therapy for pulmonary arterial hypertension","volume":"41","author":"Barst","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.rmed.2010.12.018_bib82","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s00246-005-0925-4","article-title":"Beraprost therapy in children with pulmonary hypertension secondary to congenital heart disease","volume":"26","author":"Limsuwan","year":"2005","journal-title":"Pediatr Cardiol"},{"key":"10.1016\/j.rmed.2010.12.018_bib83","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1253\/circj.71.1829","article-title":"Pilot study of short-term effects of a novel long-acting oral beraprost in patients with pulmonary arterial hypertension","volume":"71","author":"Ikeda","year":"2007","journal-title":"Circ J"},{"key":"10.1016\/j.rmed.2010.12.018_bib84","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1536\/ihj.50.513","article-title":"Effects of long-acting beraprost sodium (TRK-100STP) in Japanese patients with pulmonary arterial hypertension","volume":"50","author":"Kunieda","year":"2009","journal-title":"Int Heart J"},{"key":"10.1016\/j.rmed.2010.12.018_bib85","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.2169\/internalmedicine.48.2251","article-title":"Long-term administration of beraprost sodium for pulmonary arterial hypertension associated with congenital heart disease","volume":"48","author":"Oyamada","year":"2009","journal-title":"Intern Med"},{"key":"10.1016\/j.rmed.2010.12.018_bib86","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1164\/rccm.200505-766OC","article-title":"Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension","volume":"172","author":"Gomberg-Maitland","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmed.2010.12.018_bib87","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.amjcard.2006.09.119","article-title":"Transition of stable pediatric patients with pulmonary arterial hypertension from intravenous epoprostenol to intravenous treprostinil","volume":"99","author":"Ivy","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.rmed.2010.12.018_bib88","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1378\/chest.06-2118","article-title":"Transition from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension: a controlled trial","volume":"132","author":"Rubenfire","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2010.12.018_bib89","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/FJC.0b013e31802b3184","article-title":"Rapid switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension","volume":"49","author":"Sitbon","year":"2007","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.rmed.2010.12.018_bib90","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1378\/chest.121.5.1561","article-title":"Transitioning from i.v. epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension","volume":"121","author":"Vachiery","year":"2002","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2010.12.018_bib91","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.rmed.2007.12.020","article-title":"Long-term experience after transition from parenteral prostanoids to oral agents in patients with pulmonary hypertension","volume":"102","author":"Diaz-Guzman","year":"2008","journal-title":"Respir Med"},{"key":"10.1016\/j.rmed.2010.12.018_bib92","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.healun.2007.01.022","article-title":"Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension","volume":"26","author":"Johnson","year":"2007","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.rmed.2010.12.018_bib93","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/j.rmed.2009.05.009","article-title":"Outcome of pulmonary hypertension subjects transitioned from intravenous prostacyclin to oral bosentan","volume":"103","author":"Safdar","year":"2009","journal-title":"Respir Med"},{"key":"10.1016\/j.rmed.2010.12.018_bib94","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1378\/chest.126.3.808","article-title":"Transition from epoprostenol and treprostinil to the oral endothelin receptor antagonist bosentan in patients with pulmonary hypertension","volume":"126","author":"Suleman","year":"2004","journal-title":"Chest"}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611110005639?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611110005639?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T11:07:37Z","timestamp":1760612857000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611110005639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":94,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["S0954611110005639"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2010.12.018","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2011,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of pulmonary arterial hypertension: The role of prostacyclin and prostaglandin analogs","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2010.12.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}